Instil Bio, Inc.

TIL Nasdaq SEC CIK 1789769
Follow Instil Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$4.2M +68.9% vs same quarter last year
EPS, diluted −$0.62 +69.2% vs same quarter last year
Operating cash flow −$2.4M +77.2% vs same quarter last year
Operating income −$6M +61.3% vs same quarter last year
Net income by quarter
−$11.9M
−$28.5M
−$21.4M
−$13.6M
−$71.4M
−$4.4M
−$4.4M
−$4.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$300M−$200M−$100M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$71.4M
FY24−$74.1M
FY23−$156.1M
FY22−$223.2M
FY21−$156.8M
FY20−$37.7M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$55.7M
FY23−$102.7M
FY22−$264.8M
FY21−$180M
FY20−$80.4M
FY19-